<DOC>
	<DOCNO>NCT00003884</DOCNO>
	<brief_summary>RATIONALE : Zoledronate may help relieve symptom cause bone metastasis . It yet know zoledronate effective therapy relieve symptom bone metastases prevent disease progression . PURPOSE : Randomized phase III trial determine effectiveness zoledronate treat patient solid tumor spread bone .</brief_summary>
	<brief_title>Zoledronate Treating Patients With Solid Tumors That Have Spread Bone</brief_title>
	<detailed_description>OBJECTIVES : I. Assess safety efficacy zoledronate patient solid tumor cancer bone metastases breast prostate cancer . II . Assess efficacy zoledronate prevent skeletal-related event include tumor induce hypercalcemia ( TIH ) , time first occurrence skeletal-related event TIH , skeletal morbidity rate , time progression bone metastasis , overall survival , time overall disease progression patient . III . Assess quality life pain patient regimens . OUTLINE : This randomize , double blind , placebo control , multicenter study . Patients stratify two group : patient lung cancer patient solid tumor cancer . Patients randomly assign receive 1 follow treatment : Arm I : Patients receive intravenous zoledronate 5 minute every 3 week 9 month . Arm II : Patients receive intravenous zoledronate high dose 5 minute every 3 week 9 month . Arm III : Patients receive intravenous placebo 5 minute every 3 week 9 month . All patient receive oral calcium daily , oral multivitamin supplement . Quality life assess prior therapy , month 3 , 6 , 9 . Patients follow every 6 month survival . PROJECTED ACCRUAL : A total 600 patient accrue study within 12 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hypercalcemia</mesh_term>
	<mesh_term>Paraneoplastic Syndromes</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm diagnosis cancer breast cancer , multiple myeloma , prostate cancer Objective evidence bone metastasis discover within 6 week study entry ( patient screen present ECOG score 2 ) No study entry restriction bone metastases patient ECOG 0 1 No symptomatic brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2.5 mg/dL liver metastases Renal : Creatinine great 3.0 mg/dL Calcium least 8.0 mg/dL less 12.0 mg/dL Cardiovascular : No history severe cardiovascular disease within past 6 month ( e.g. , congestive heart failure ) No hypertension refractory treatment No symptomatic coronary artery disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history noncompliance medical regimen PRIOR CONCURRENT THERAPY : Biologic therapy : Concurrent biologic response modifier therapy allow Concurrent market cytokine colony stimulate factor therapy allow Chemotherapy : Concurrent market chemotherapy agent allow ( include open label cooperative trial supportive care ) Endocrine therapy : Concurrent hormonal agent steroid therapy allow Concurrent corticosteroid therapy allow ( chemotherapy induce nausea/vomiting spinal compression ) Radiotherapy : Concurrent radiotherapy treat extraskeletal and/or skeletal tumor site allow Surgery : Prior surgery treat prevent pathological fracture spinal cord compression allow Other : At least 30 day since prior investigational drug No concurrent bisphosphonate agent At least 30 day since prior bisphosphonate agent ( single exposure allow within prior 12 month )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>hypercalcemia malignancy</keyword>
	<keyword>pain</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>bone metastasis</keyword>
</DOC>